|
KMID : 1030220210220020097
|
|
Journal of Korean Diabetes
2021 Volume.22 No. 2 p.97 ~ p.104
|
|
|
Recent Perspective on Thiazolidinedione
|
|
Kim Won-Jun
|
|
|
Abstract
|
|
|
|
Thiazolidinedione (TZD) is an insulin sensitizer that improves insulin resistance in the adipose tissue, liver, and muscles and has a pancreas-protective effect while inhibiting gluconeogenesis. Its other advantages include a glucose lowering effect, its durability, cardiovascular benefit, and recent evidence in nonalcoholic fatty liver disease and dementia. However, there are also concerns about fluid retention/edema/heart failure, bladder cancer, and fractures with TZD use. TZD can still be a useful option for diabetes treatment when calculating risk versus benefit, but appropriate selection of patients is needed.
|
|
|
KEYWORD
|
|
|
Diabetes mellitus, type 2, Hypoglycemic agents, Pioglitazone, Thiazolidinediones
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|